The Cause

DesiCorp is at the forefront of developing a freeze-dried blood product designed for immediate infusion at the point of injury on the battlefield, as well as for patients in remote or austere locations suffering from traumatic blood loss. According to the Department of Defense, over 90% of potentially survivable battlefield deaths are due to severe blood loss that could be mitigated with timely transfusions. Additionally, 80% of post-treatment fatalities are linked to delays in addressing blood loss. These preventable deaths make up nearly 25% of U.S. warfighter casualties. Recognizing this critical medical challenge since World War II, the U.S. military has prioritized the development and acquisition of freeze-dried blood units since 1941.